Tag: EGRF mutated
In the ADAURA phase III trial, Tagrisso from AstraZeneca showed a significant improvement in overall survival for patients with early-stage EGFR-mutated lung cancer.
Statistically significant and clinically meaningful improvements in overall survival (OS), a crucial secondary endpoint, were seen with AstraZeneca’s…
Registration Form
This will close in 0 seconds
